Physician profile
Harrell A Grand
NPI 1982623252
$10,795.84
in general payments reported to CMS, 2019-2025
47 companies · $771 in 2025
The $771 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $2,180 · 2021: $2,410 · 2022: $1,688 · 2023: $1,026 · 2024: $564 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,719.53 | 2019-2025 | Dovato, Apretude |
| Amarin Pharma, INC. | $951.26 | 2019-2022 | |
| Abbvie INC. | $735.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $654.34 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $624.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $600.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.53 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $342.83 | 2019-2021 | |
| Amgen INC. | $238.60 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $222.95 | 2019-2023 | Livalo, Seglentis |
| Janssen Biotech, INC. | $216.71 | 2019-2023 | Symtuza |
| Antares Pharma, INC. | $213.22 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $195.72 | 2019-2024 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $179.64 | 2020-2022 | |
| Madrigal Pharmaceuticals | $174.18 | 2025 | Rezdiffra |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrell Grand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.